4.6 Article

TGF-β3 Inhibits Antibody Production by Human B Cells

Journal

PLOS ONE
Volume 12, Issue 1, Pages -

Publisher

PUBLIC LIBRARY SCIENCE
DOI: 10.1371/journal.pone.0169646

Keywords

-

Funding

  1. Ministry of Education, Culture, Sports, Science and Technology, KAKENHI from Japan Society for the Promotion of Science [23229007, 15K19566]
  2. Grants-in-Aid for Scientific Research [15K19566, 23229007, 16K15510, 15H05787] Funding Source: KAKEN

Ask authors/readers for more resources

TGF-beta is a pleotropic cytokine involved in various biological processes. Of the three isoforms of TGF-beta, TGF-beta 1 has long been recognized as an important inhibitory cytokine in the immune system and has been reported to inhibit B cell function in both mice and humans. Recently, it has been suggested that TGF-beta 3 may play an important role in the regulation of immune system in mice. Murine CD4(+)CD25(-)LAG3(+) regulatory T cells suppress B cell function through the production of TGF-beta 3, and it has been reported that TGF-beta 3 is therapeutic in a mouse model of systemic lupus erythematosus. The effect of TGF-beta 3 on human B cells has not been reported, and we herein examined the effect of TGF-beta 3 on human B cells. TGF-beta 3 suppressed B cell survival, proliferation, differentiation into plasmablasts, and antibody secretion. Although the suppression of human B cells by TGF-beta 1 has long been recognized, the precise mechanism for the suppression of B cell function by TGF-beta 1 remains elusive; therefore, we examined the effect of TGF-beta 1 and beta 3 on pathways important in B cell activation and differentiation. TGF-beta 1 and TGF-beta 3 inhibited some of the key molecules of the cell cycle, as well as transcription factors important in B cell differentiation into antibody secreting cells such as IRF4, Blimp-1, and XBP1. TGF-beta 1 and beta 3 also inhibited B cell receptor signaling. Our results suggest that TGF-beta 3 modifying therapy might be therapeutic in autoimmune diseases with B cell dysregulation in humans.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Rheumatology

Cost-effectiveness analyses of biologic and targeted synthetic disease-modifying anti-rheumatic diseases in patients with rheumatoid arthritis: Three approaches with a cohort simulation and real-world data

Masataka Kuwana, Naoto Tamura, Shinsuke Yasuda, Keishi Fujio, Ayako Shoji, Hiroko Yamaguchi, Katsuhiko Iwasaki, Misako Makishima, Yuichi Kawata, Katsuhisa Yamashita, Ataru Igarashi

Summary: This study assessed the cost-effectiveness of biologic and targeted synthetic disease-modifying anti-rheumatic drugs (b/tsDMARDs) in the treatment of rheumatoid arthritis. The results showed that b/tsDMARDs with lower prices demonstrated higher cost-effectiveness.

MODERN RHEUMATOLOGY (2023)

Article Rheumatology

Combined plasma metabolomic and transcriptomic analysis identify histidine as a biomarker and potential contributor in SLE pathogenesis

Yukiko Iwasaki, Yusuke Takeshima, Masahiro Nakano, Mai Okubo, Mineto Ota, Akari Suzuki, Yuta Kochi, Tomohisa Okamura, Takaho Endo, Ichiro Miki, Kazuhiro Sakurada, Kazuhiko Yamamoto, Keishi Fujio

Summary: This study explored the potential of plasma histidine levels as biomarkers for SLE patients. The results showed that histidine, along with other amino acids, could effectively distinguish between SLE patients and healthy controls. Furthermore, a decrease in histidine levels correlated with disease damage accrual, suggesting its involvement in SLE pathogenesis.

RHEUMATOLOGY (2023)

Article Immunology

Significance of anti-transcobalamin receptor antibodies in cutaneous arteritis revealed by proteome-wide autoantibody screening

Kazuki M. Matsuda, Hirohito Kotani, Kei Yamaguchi, Taishi Okumura, Eriko Fukuda, Masanori Kono, Teruyoshi Hisamoto, Ruriko Kawanabe, Yuta Norimatsu, Ai Kuzumi, Maiko Fukayama, Takemichi Fukasawa, Satoshi Ebata, Asako Yoshizaki-Ogawa, Tomohisa Okamura, Hirofumi Shoda, Keishi Fujio, Naoki Goshima, Shinichi Sato, Ayumi Yoshizaki

Summary: Cutaneous arteritis (CA) is a skin vasculitis that affects small to medium-sized arteries. The diagnosis relies on skin biopsy, which can be burdensome. The pathogenesis and treatment of CA are still unclear. In this study, anti-transcobalamin receptor (TCblR) antibodies were found in 24% of CA patients and were associated with skin-limited CA. These antibodies trigger interleukin-6 autocrine loop and induce periarterial inflammation. Methylcobalamin, a ligand of TCblR, can ameliorate inflammation caused by these antibodies. These findings suggest that anti-TCblR antibodies could be a diagnostic marker and a therapeutic target for CA.

JOURNAL OF AUTOIMMUNITY (2023)

Article Rheumatology

Immunomics analysis of rheumatoid arthritis identified precursor dendritic cells as a key cell subset of treatment resistance

Saeko Yamada, Yasuo Nagafuchi, Min Wang, Mineto Ota, Hiroaki Hatano, Yusuke Takeshima, Mai Okubo, Satomi Kobayashi, Yusuke Sugimori, Nakano Masahiro, Ryochi Yoshida, Norio Hanata, Yuichi Suwa, Yumi Tsuchida, Yukiko Iwasaki, Shuji Sumitomo, Kanae Kubo, Kenichi Shimane, Keigo Setoguchi, Takanori Azuma, Hiroko Kanda, Hirofumi Shoda, Xuan Zhang, Kazuhiko Yamamoto, Kazuyoshi Ishigaki, Tomohisa Okamura, Keishi Fujio

Summary: By analyzing the transcriptome of peripheral blood immune cell subsets in patients with rheumatoid arthritis (RA), immune cells that predict treatment resistance were identified. Changes in the transcriptome and treatment effects in RA were characterized. Plasmacytoid dendritic cells (pDC) showed the strongest association with treatment resistance. The predictive value of pDC-related gene expression and pDC proportion in treatment-resistant patients was validated in independent cohorts.

ANNALS OF THE RHEUMATIC DISEASES (2023)

Review Medicine, General & Internal

Role of autotaxin in systemic lupus erythematosus

Yumi Tsuchida, Hirofumi Shoda, Tetsuji Sawada, Keishi Fujio

Summary: Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease characterized by the production of autoantibodies and immune complex deposition. Autotaxin (ATX), which catalyzes the production of lysophosphatidic acid, has been identified as a potential biomarker in SLE. Increased levels of ATX have been found in the serum and urine of patients with SLE and lupus nephritis. Recent studies suggest that ATX produced by plasmacytoid dendritic cells may have an important role in SLE pathogenesis, and it is associated with type I interferons. ATX may be a valuable biomarker and key molecule in SLE.

FRONTIERS IN MEDICINE (2023)

Article Medicine, General & Internal

Anti-synthetase Syndrome That Relapsed with Pulmonary Arterial Hypertension and Malignancy

Hideki Oka, Shuji Sumitomo, Hayato Shimizu, Maki Kanamori, Shiori Murata, Daisuke Yamashita, Taiji Okada, Hiroaki Nishioka, Koichiro Ohmura

Summary: This case report reveals the relationship between anti-synthetase syndrome and pulmonary artery hypertension, as well as malignancy.

INTERNAL MEDICINE (2023)

Article Immunology

Functional evaluation of rare OASL variants by analysis of SLE patient-derived iPSCs

Bunki Natsumoto, Hirofumi Shoda, Yasuo Nagafuchi, Mineto Ota, Takashi Okumura, Yumi Horie, Tomohisa Okamura, Kazuhiko Yamamoto, Motonori Tsuji, Makoto Otsu, Hideki Taniguchi, Keishi Fujio

Summary: In this study, patient-derived induced pluripotent stem cells (iPSCs) were used in combination with genetic analysis to identify and elucidate the biological functions of rare variants underlying systemic lupus erythematosus (SLE). It was found that a rare variant in the OASL gene was shared between SLE-iPSCs and another independent SLE patient, and there was a significant accumulation of OASL variants among SLE patients. Additionally, genome editing experiments confirmed the impact of these variants on type 1 interferon secretion in immune cells.

JOURNAL OF AUTOIMMUNITY (2023)

Article Rheumatology

Synovial Tissue Heterogeneity in Japanese Patients With Rheumatoid Arthritis Elucidated Using a Cell-Type Deconvolution Approach

Sotaro Nakajima, Haruka Tsuchiya, Mineto Ota, Megumi Ogawa, Saeko Yamada, Ryochi Yoshida, Junko Maeda, Harumi Shirai, Taro Kasai, Jun Hirose, Keita Ninagawa, Yuichiro Fujieda, Takeshi Iwasaki, Yoshimi Aizaki, Hiroshi Kajiyama, Masakazu Matsushita, Eiryo Kawakami, Naoto Tamura, Toshihide Mimura, Koichiro Ohmura, Akio Morinobu, Tatsuya Atsumi, Yoshiya Tanaka, Tsutomu Takeuchi, Sakae Tanaka, Tomohisa Okamura, Keishi Fujio

Summary: This study utilized single-cell RNA sequencing technology to stratify and analyze the synovium of East Asian patients with rheumatoid arthritis (RA), revealing the heterogeneity of immune cell compositions and providing insights into the inflammatory drivers. The findings highlight the potential of evaluating the site of inflammation for personalized drug selection.

ARTHRITIS & RHEUMATOLOGY (2023)

Article Rheumatology

Transcriptome Profiling of Immune Cell Types in Peripheral Blood Reveals Common and Specific Pathways Involved in the Pathogenesis of Myositis-Specific Antibody-Positive Inflammatory Myopathies

Yusuke Sugimori, Yukiko Iwasaki, Yusuke Takeshima, Mai Okubo, Satomi Kobayashi, Hiroaki Hatano, Saeko Yamada, Masahiro Nakano, Ryochi Yoshida, Mineto Ota, Yumi Tsuchida, Yasuo Nagafuchi, Kenichi Shimane, Ken Yoshida, Daitaro Kurosaka, Shuji Sumitomo, Hirofumi Shoda, Kazuhiko Yamamoto, Tomohisa Okamura, Keishi Fujio

Summary: Transcriptome analysis identified common or specific immunological pathways in different immune cell types of patients with idiopathic inflammatory myopathies (IIM) based on their clinical phenotypes and myositis-specific antibodies (MSAs). B cells may play a significant role in both common and specific immunological pathways in IIM.

ACR OPEN RHEUMATOLOGY (2023)

Letter Rheumatology

Resolution of exacerbated rheumatoid arthritis-associated interstitial lung disease under baricitinib treatment

T. Komai, T. Sawada, H. Tsuchiya, H. Harada, H. Shoda, K. Fujio

SCANDINAVIAN JOURNAL OF RHEUMATOLOGY (2023)

Article Rheumatology

Long-term risks of malignancy in myositis-specific antibody-positive idiopathic inflammatory myopathy

Shinji Izuka, Toshihiko Komai, Hirofumi Shoda, Keishi Fujio

Summary: This study found that patients with myositis-specific antibody (MSA)-positive idiopathic inflammatory myopathy (IIM), specifically those with anti-MDA5 and anti-TIF1-gamma antibodies, have an increased long-term risk of malignancy. Screening for malignancies in patients with late phase of IIM and an anti-MDA5 antibody may be beneficial.

RHEUMATOLOGY INTERNATIONAL (2023)

Article Rheumatology

Four cases of dermatomyositis with abnormally high anti-MDA-5 antibody titres and not high levels of serum ferritin

Daichi Umemoto, Shuji Sumitomo, Shohei Fujita, Hayato Shimizu, Hideki Oka, Maki Kanamori, Hiroaki Nishioka, Koichiro Ohmura

Summary: Patients with abnormally high anti-MDA-5 antibody titres may experience disease progression even if ferritin levels are not high and lung shadows are minimal. Therefore, early intensive treatment is necessary regardless of serum ferritin level.

MODERN RHEUMATOLOGY CASE REPORTS (2023)

Article Rheumatology

A case of aortoduodenal fistula caused by IgG4-related periaortitis

Hideki Oka, Shuji Sumitomo, Hayato Shimizu, Maki Kanamori, Daisuke Yamashita, Hiroaki Nishioka, Koichiro Ohmura

Summary: An 86-year-old man who had undergone endovascular aortic repair for an abdominal aortic aneurysm with impending rupture presented to the hospital due to fatigue and black stools. The diagnosis of aortic duodenal fistula was confirmed and emergency abdominal aortic replacement was performed. Pathological findings revealed the presence of numerous IgG4-positive plasma cells infiltrating the aortic wall, leading to a diagnosis of IgG4-related periaortitis.

MODERN RHEUMATOLOGY CASE REPORTS (2023)

No Data Available